Novavax, Inc. (NASDAQ:NVAX) Sees Large Decline in Short Interest

Paterniano Del Favero
Luglio 28, 2017

(NASDAQ:NVAX) on Friday, September 16 to "Neutral" rating. Novavax presently has a consensus rating of "Hold" and a consensus price target of $5.61.

Several other research analysts have also commented on the stock. BidaskClub cut shares of Novavax from a hold rating to a sell rating in a research note on Wednesday, July 19th. Zacks Investment Research upgraded Novavax from a "hold" rating to a "buy" rating and set a $1.25 price target on the stock in a research report on Saturday, June 10th. Finally, ValuEngine cut shares of Novavax from a sell rating to a strong sell rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, nine have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Piper Jaffray maintained it with "Hold" rating and $1.5000 target in Monday, July 24 report. (NASDAQ:NVAX) opened at 1.02 on Friday. A total of 8.76 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 7.45 Million shares, while its relative volume stands at 1.19. Novavax Inc (NASDAQ:NVAX)'s price sits -9.9% off from its 50-day moving average of $1.18 and -18.53% away from the stock's 200-day moving average which is $1.18. The company's market capitalization is $285.42 million. (NASDAQ:NVAX) to report $-0.16 EPS on August, 8.They anticipate $0.13 EPS change or 44.83% from last quarter's $-0.29 EPS. (NASDAQ:NVAX). Moreover, Lpl Fincl Ltd Llc has 0% invested in Novavax, Inc. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.02. The company now has a Return on Equity of -787.4% and a Return on Investment of 0%. The business had revenue of $5.68 million for the quarter, compared to analysts' expectations of $6.17 million. During the same period a year ago, the firm earned ($0.29) earnings per share. The firm's revenue for the quarter was up 34.6% on a year-over-year basis. Analysts expect that Novavax will post ($0.61) EPS for the current year.

ILLEGAL ACTIVITY WARNING: "Novavax's (NVAX) Hold Rating Reiterated at Piper Jaffray Companies" was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was stolen and reposted in violation of U.S. & global trademark & copyright laws. The original version of this article can be viewed at https://stocknewstimes.com/2017/07/28/piper-jaffray-companies-reiterates-hold-rating-for-novavax-inc-nvax.html.

In other news, insider Stanley C. Erck bought 50,000 shares of the business's stock in a transaction on Thursday, May 11th. The shares were purchased at an average cost of $0.84 per share, with a total value of $42,000.00. Following the completion of the purchase, the insider now owns 128,279 shares of the company's stock, valued at $107,754.36. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders purchased a total of 105,000 shares of company stock worth $90,800 in the last 90 days. Corporate insiders own 4.00% of the company's stock. Hsbc Hldgs Public Limited Company invested in 0% or 46,516 shares. NY raised its stake in shares of Novavax by 2.9% in the fourth quarter. Creative Planning now owns 472,198 shares of the biopharmaceutical company's stock valued at $543,000 after buying an additional 148,139 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Novavax during the first quarter worth $157,000. KCG Holdings Inc. now owns 178,797 shares of the biopharmaceutical company's stock valued at $229,000 after buying an additional 110,292 shares during the last quarter. NY now owns 203,996 shares of the biopharmaceutical company's stock worth $257,000 after buying an additional 5,704 shares in the last quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company's stock worth $184,000 after buying an additional 5,250 shares in the last quarter. Finally, KCG Holdings Inc. raised its stake in Novavax by 161.0% in the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company's stock valued at $213,000 after buying an additional 10,965 shares in the last quarter.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE